Show simple item record

dc.contributor.authorMacias García, Paloma 
dc.contributor.authorRashid Abdu Rahim López, Raúl 
dc.contributor.authorCruz Gómez, Álvaro Javier 
dc.contributor.authorLozano Soto, Elena María 
dc.contributor.authorSanmartino, Florencia Soledad 
dc.contributor.authorEspinosa Rosso, Raúl
dc.contributor.authorGonzález Rosa, Javier Jesús 
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2022-07-13T07:56:04Z
dc.date.available2022-07-13T07:56:04Z
dc.date.issued2022-05
dc.identifier.issn0953-4180
dc.identifier.urihttp://hdl.handle.net/10498/27170
dc.description.abstractBackground. Neuropsychiatric symptoms (NPS) are a common and potentially serious manifestation of Parkinson's disease (PD) but are frequently overlooked in favor of a focus on motor symptomatology. Here, we conducted a literature review of the prevalence and type of NPS experienced by PD patients with a clinically defined course of their illness. Methods. We identified reports of NPS in patients with PD and mean disease duration over 3 years. Three databases-PubMed, Scopus, and Dialnet-were searched for relevant literature published between 2010 and 2020. Predefined exclusion criteria were applied prior to a descriptive analysis of the literature base. Results. In all, 87 unique reports were identified and 30 met inclusion and exclusion criteria. These included 7142 patients with PD (male: 67.3%; mean age: 66.2 years; mean disease duration: 6.7 years). The most frequent NPS were mood disorders (apathy, depression, and anxiety), psychosis, and impulse control disorders (ICD). Treatment with dopamine agonists was identified as an important risk factor for ICD. Co-occurrence of NPS and cognitive dysfunction was also evidenced in a number of studies. Patients with more significant cognitive deficits and higher levels of NPS appeared to be of older age with a longer disease duration and to have more severe motor symptoms. Conclusions. NPS, most commonly mood disorders (apathy, depression, and anxiety), psychosis, and ICDs are frequent manifestations of PD. The results of this review reflect the need to develop unified validated assessment protocols for NPS in PD, as well as to improve their management in clinical practice.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherHINDAWI LTDes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBehavioural Neurology, vol. 2022, Article ID 1213393, 16 pages, 2022es_ES
dc.titleNeuropsychiatric Symptoms in Clinically Defined Parkinson's Disease: An Updated Review of Literaturees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1155/2022/1213393
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/PSI2017-85951-R/ES/EVALUANDO LA INTEGRIDAD DE LAS REDES FUNCIONALES CORTICO-SUBCORTICALES MEDIANTE ESTIMULACION CEREBRAL PROFUNDA DEL NUCLEO ACCUMBENS Y DEL NUCLEO SUBTALAMICO/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//PI-0025-2017es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//PI-0034-2019es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional